At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 68 enrolled
Drug / intervention
non-smoker oral melatonin +3 moredrug
Likely dose
non-smoker oral melatonin 3 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Protective Effect of Melatonin on Smoke-induced Vascular Injury in Human
In Brief
A Phase 4 clinical trial evaluating non-smoker oral placebo, non-smoker oral melatonin, and 2 other interventions for Smoking and Vascular System Injuries. Completed, enrolled 68 participants across 1 site.
Detailed Summary
The main purpose of this study was to evaluate the effects of melatonin in the regulation of the vascular injury in smokers through population-based, randomized, double-blind, placebo-controlled trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking, Vascular System Injuries
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartJun 2015
Primary CompletionJul 2015
Study CompletionOct 2015
First PostedOct 2015
TodayJul 2026
First PostedOct 29, 2015
Enrollment StartJun 1, 2015
Primary CompletionJul 1, 2015
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 10.7 years ago
Interventions
non-smoker oral placeboother
Participants oral placebo last 2 weeks.
non-smoker oral melatonindrug
Participants oral melatonin 3 mg/day last 2 weeks.
smoker oral placeboother
Participants oral placebo last 2 weeks.
smoker oral melatonindrug
Participants oral melatonin 3 mg/day last 2 weeks.